Deidra C. Crews

Deidra C. Crews

Auto-generated profile, based on publicly available information

Deidra C. Crews

Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
CDCynthia Delgado
Cynthia Delgado
MBMukta Baweja
Mukta Baweja
DCDeidra C. Crews
Deidra C. Crews
NENwamaka D. Eneanya
Nwamaka D. Eneanya
CGCrystal A. Gadegbeku
Crystal A. Gadegbeku
NPNeil R. Powe
Neil R. Powe
Significance Statement: A Task Force from the National Kidney Foundation and American Society of Nephrology developed recommendations for reassessing inclusion of race in the estimation of GFR in the United States. The Task Force recommends immediate implementation of the Chronic Kidney Disease Epidemiology Collaboration creatinine equation refit without the race variable in all laboratories because the calculation does not include race, it included diversity in its development, its potential adverse consequences do not disproportionately affect any one group, and it is immediately available to all laboratories. A second recommendation calls for national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm eGFR in adults for clinical decision making. A third recommendation encourages research on GFR estimation with new endogenous filtration markers and interventions to eliminate racial and ethnic disparities. Background: In response to a national call for re-evaluation of the use of race in clinical algorithms, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a Task Force to reassess inclusion of race in the estimation of GFR in the United States and its implications for diagnosis and management of patients with, or at risk for, kidney diseases. Process & Deliberations: The Task Force organized its activities over 10 months in phases to (1) clarify the problem and evidence regarding eGFR equations in the United States (described previously in an interim report), and, in this final report, (2) evaluate approaches to address use of race in GFR estimation, and (3) provide recommendations. We identified 26 approaches for the estimation of GFR that did or did not consider race and narrowed our focus, by consensus, to five of those approaches. We holistically evaluated each approach considering six attributes: assay availability and standardization; implementation; population diversity in equation development; performance compared with measured GFR; consequences to clinical care, population tracking, and research; and patient centeredness. To arrive at a unifying approach to estimate GFR, we integrated information and evidence from many sources in assessing strengths and weaknesses in attributes for each approach, recognizing the number of Black and non-Black adults affected. Recommendations: (1) For US adults (>85% of whom have normal kidney function), we recommend immediate implementation of the CKD-EPI creatinine equation refit without the race variable in all laboratories in the United States because it does not include race in the calculation and reporting, included diversity in its development, is immediately available to all laboratories in the United States, and has acceptable performance characteristics and potential consequences that do not disproportionately affect any one group of individuals. (2) We recommend national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm eGFR in adults who are at risk for or have CKD, because combining filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone. If ongoing evidence supports acceptable performance, the CKD-EPI eGFR–cystatin C (eGFRcys) and eGFR creatinine–cystatin C (eGFRcr-cys_R) refit without the race variables should be adopted to provide another first-line test, in addition to confirmatory testing. (3) Research on GFR estimation with new endogenous filtration markers and on interventions to eliminate race and ethnic disparities should be encouraged and funded. An investment in science is needed for newer approaches that generate accurate, unbiased, and precise GFR measurement and estimation without the inclusion of race, and that promote health equity and do not generate disparate care. Implementation: This unified approach, without specification of race, should be adopted across the United States. High-priority and multistakeholder efforts should implement this solution.

1 June 2010 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
DCDeidra C. Crews
Deidra C. Crews
RCRaquel F. Charles
Raquel F. Charles
MEMichele K. Evans
Michele K. Evans
AZAlan B Zonderman
Alan B Zonderman
NPNeil R. Powe
Neil R. Powe

8 January 2014 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
DCDeidra C. Crews
Deidra C. Crews
MKMarie Fanelli Kuczmarski
Marie Fanelli Kuczmarski
VGVanessa Grubbs
Vanessa Grubbs
EHElizabeth Hedgeman
Elizabeth Hedgeman
VSVahakn B. Shahinian
Vahakn B. Shahinian
FTfor the Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team
for the Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team
Background: The relation of food insecurity (inability to acquire nutritionally adequate and safe foods) and chronic kidney disease (CKD) is unknown. We examined whether food insecurity is associated with prevalent CKD among lower-income individuals in both the general US adult population and an urban population. Methods: We conducted cross-sectional analyses of lower-income participants of the National Health and Nutrition Examination Survey (NHANES) 2003-2008 (n = 9,126) and the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study (n = 1,239). Food insecurity was defined based on questionnaires and CKD was defined by reduced estimated glomerular filtration rate or albuminuria; adjustment was performed with multivariable logistic regression. Results: In NHANES, the age-adjusted prevalence of CKD was 20.3, 17.6, and 15.7% for the high, marginal, and no food insecurity groups, respectively. Analyses adjusting for sociodemographics and smoking status revealed high food insecurity to be associated with greater odds of CKD only among participants with either diabetes (OR = 1.67, 95% CI: 1.14-2.45 comparing high to no food insecurity groups) or hypertension (OR = 1.37, 95% CI: 1.03-1.82). In HANDLS, the age-adjusted CKD prevalence was 5.9 and 4.6% for those with and without food insecurity, respectively (p = 0.33). Food insecurity was associated with a trend towards greater odds of CKD (OR = 1.46, 95% CI: 0.98-2.18) with no evidence of effect modification across diabetes, hypertension, or obesity subgroups. Conclusion: Food insecurity may contribute to disparities in kidney disease, especially among persons with diabetes or hypertension, and is worthy of further study.

6 February 2009 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
BJBernard G Jaar
Bernard G Jaar
LPLaura C Plantinga
Laura C Plantinga
DCDeidra C Crews
Deidra C Crews
NFNancy E Fink
Nancy E Fink
NHNasser Hebah
Nasser Hebah
NPNeil R Powe
Neil R Powe
The use of peritoneal dialysis (PD) has declined in the United States over the past decade and technique failure is also reportedly higher in PD compared to hemodialysis (HD), but there are little data in the United States addressing the factors and outcomes associated with switching modalities from PD to HD.

1 May 2010 in Hypertension
Verified
Journal Article
Closed access
PDF file
DCDeidra C. Crews
Deidra C. Crews
LPLaura C. Plantinga
Laura C. Plantinga
EMEdgar R. Miller
Edgar R. Miller
RSRajiv Saran
Rajiv Saran
EHElizabeth Hedgeman
Elizabeth Hedgeman
NPNeil R. Powe
Neil R. Powe
Hypertension is both a cause and a consequence of chronic kidney disease, but the prevalence of chronic kidney disease throughout the diagnostic spectrum of blood pressure has not been established. We determined the prevalence of chronic kidney disease within blood pressure categories in 17 794 adults surveyed by the National Health and Nutrition Examination Survey during 1999–2006. Diagnosed hypertension was defined as self-reported provider diagnosis (n=5832); undiagnosed hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, without report of provider diagnosis (n=3046); prehypertension was defined as systolic blood pressure ≥120 and <140 mm Hg or diastolic blood pressure ≥80 and <90 mm Hg (n=3719); and normal was defined as systolic blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg (n=5197). Chronic kidney disease was defined as estimated glomerular filtration rate 30 mg/g. Prevalences of chronic kidney disease among those with prehypertension and undiagnosed hypertension were 17.3% and 22.0%, respectively, compared with 27.5% with diagnosed hypertension and 13.4% with normal blood pressure, after adjustment for age, sex, and race in multivariable logistic regression. This pattern persisted with varying definitions of kidney disease; macroalbuminuria (urinary albumin:creatinine ratio >300 mg/g) had the strongest association with increasing blood pressure category (odds ratio: 2.37 [95% CI: 2.00 to 2.81]). Chronic kidney disease is prevalent in undiagnosed and prehypertension. Earlier identification and treatment of both these conditions may prevent or delay morbidity and mortality from chronic kidney disease.

1 May 2014 in Current Opinion in Nephrology and Hypertension
Verified
Journal Article
Closed access
DCDeidra C. Crews
Deidra C. Crews
YLYang Liu
Yang Liu
LBL. Ebony Boulware
L. Ebony Boulware
Purpose of review Racial, ethnic and socioeconomic disparities in chronic kidney disease (CKD) have been documented for decades, yet little progress has been made in mitigating them. Several recent studies offer new insights into the root causes of these disparities, point to areas in which future research is warranted, and identify opportunities for changes in policy and clinical practice. Recent findings Recently published evidence suggests that geographic disparities in CKD prevalence exist and vary by race. CKD progression is more rapid for racial and ethnic minority groups compared with whites and may be largely, but not completely, explained by genetic factors. Stark socioeconomic disparities in outcomes for dialysis patients exist and vary by race, place of residence, and treatment facility. Disparities in access to living kidney donation may be driven primarily by the socioeconomic status of the donor as opposed to recipient factors. Summary Recent studies highlight opportunities to eliminate disparities in CKD, including efforts to direct resources to areas and populations where disparities are most prevalent, efforts to understand how to best use emerging information on the contribution of genetic factors to disparities, and continued work to identify modifiable environmental, social, and behavioral factors for targeted interventions among high-risk populations.